Because patients who discontinued WEGOVY injection during titration and those who did not reach the 2.4 mg weekly dose were not eligible for the randomized-treatment period, the results may not reflect the experience of patients in the general population who are first starting WEGOVY injection
To clarify the possible interactions between GLP-1 mimetics and ketogenesis in diabetes, this review was undertaken to collate and interpret the literature
GLP-1RAs with proven benefit are even recommended as a first-line therapy in people with T2D and atherosclerotic CVD or at high/very high CV risk without prescribing metformin (20), despite the fact that CVOTs testing GLP-1RAs have mainly been performed in metformin-treated patients
Tabk AG, Herder C, Rathmann W, Brunner EJ, Kivimki M
Bray underscored the urgency: It sounds like this is already having an impact on every single food and beverage company out there and will only continue to have more of an impact as adoption of this medication continues to grow. Everyones Job Austin stressed that the GLP-1 effect touches every part of the business
